Table 2.
Baseline characteristics of the PCI+ and PCI−/IHD− groups
| All patients (n = 27,676) | Entire cohort | Propensity score-matched sample | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCI+ (n = 282) | PCI−/IHD+ (n = 27,392) | SD* | PCI+ (n = 280) | PCI−/IHD+ (n = 280) | SD* | |||||||
| Age, mean ± standard deviance | 70 | ± 10.2 | 73 | ± 6.9 | 70 | ± 10.2 | 0.822 | 73 | ± 7.0 | 73 | ± 8.4 | 0.027 |
| Sex | 0.444 | 0.077 | ||||||||||
| Female | 8563 | (31) | 37 | (13) | 8526 | (31) | 37 | (13) | 30 | (11) | ||
| Male | 19,111 | (69) | 245 | (87) | 18,866 | (69) | 243 | (87) | 250 | (89) | ||
| Cancer type | ||||||||||||
| Colorectal cancer | 9807 | (35) | 95 | (34) | 9712 | (35) | 0.037 | 95 | (34) | 97 | (35) | 0.015 |
| Lung cancer | 5997 | (22) | 68 | (24) | 5929 | (22) | 0.059 | 67 | (24) | 62 | (22) | 0.042 |
| Prostate cancer | 4317 | (16) | 55 | (20) | 4262 | (16) | 0.104 | 55 | (20) | 57 | (20) | 0.018 |
| Gastric cancer | 7553 | (27) | 64 | (22) | 7489 | (27) | 0.107 | 63 | (22) | 64 | (23) | 0.009 |
| Cancer stage | ||||||||||||
| In situ | 2569 | (9) | 21 | (7) | 2548 | (9) | 0.067 | 21 | (7) | 13 | (5) | 0.120 |
| Localised | 12,738 | (46) | 148 | (52) | 12,590 | (46) | 0.131 | 147 | (53) | 163 | (58) | 0.115 |
| Regional to lymph nodes involved | 2924 | (11) | 39 | (14) | 2885 | (11) | 0.101 | 39 | (14) | 31 | (11) | 0.086 |
| Regional by direct extension | 2818 | (10) | 36 | (13) | 2782 | (10) | 0.082 | 35 | (12) | 38 | (14) | 0.032 |
| Distant site(s)/node(s) involved | 5852 | (21) | 31 | (11) | 5821 | (21) | 0.282 | 31 | (11) | 32 | (11) | 0.011 |
| Unknown | 773 | (3) | 7 | (3) | 766 | (3) | 0.020 | 7 | (3) | 3 | (1) | 0.108 |
| Barthel index score | ||||||||||||
| 60–100 | 25,701 | (93) | 267 | (95) | 25,434 | (93) | 0.076 | 265 | (95) | 264 | (94) | 0.016 |
| 40–59 | 694 | (2) | 3 | (1) | 691 | (2) | 0.110 | 3 | (1) | 2 | (1) | 0.038 |
| 0–39 | 1279 | (5) | 12 | (4) | 1267 | (5) | 0.018 | 12 | (4) | 14 | (5) | 0.034 |
| Overweight | 6116 | (22) | 85 | (30) | 6031 | (22) | 0.186 | 84 | (30) | 85 | (30) | 0.008 |
| Current or past smoking | 14,138 | (51) | 168 | (60) | 13,970 | (51) | 0.173 | 166 | (59) | 165 | (59) | 0.007 |
| Dyslipidemia | 562 | (2) | 16 | (6) | 546 | (2) | 0.193 | 15 | (5) | 13 | (5) | 0.033 |
| Hypertension | 1393 | (5) | 29 | (10) | 1364 | (5) | 0.201 | 27 | (10) | 19 | (7) | 0.104 |
| Diabetes mellitus | 1137 | (4) | 34 | (12) | 1103 | (4) | 0.299 | 32 | (11) | 23 | (8) | 0.108 |
| Chronic kidney disease | 220 | (1) | 13 | (5) | 207 | (1) | 0.240 | 11 | (4) | 8 | (3) | 0.059 |
| Congestive heart failure | 250 | (1) | 11 | (4) | 239 | (1) | 0.199 | 9 | (3) | 4 | (1) | 0.119 |
| Atrial fibrillation | 308 | (1) | 0 | (0) | 308 | (1) | 0.151 | 0 | (0) | 0 | (0) | NA |
| β-blocker | 562 | (2) | 31 | (11) | 532 | (2) | 0.374 | 28 | (10) | 23 | (8) | 0.062 |
| Statin | 1251 | (5) | 46 | (16) | 1205 | (4) | 0.399 | 44 | (16) | 44 | (16) | 0.000 |
| ACE inhibitor | 301 | (1) | 9 | (3) | 292 | (1) | 0.065 | 9 | (3) | 2 | (1) | 0.181 |
| ARB | 1755 | (6) | 49 | (17) | 1707 | (6) | 0.343 | 46 | (16) | 43 | (15) | 0.029 |
| Oral anti-coagulants | 247 | (1) | 8 | (3) | 239 | (1) | 0.060 | 8 | (3) | 3 | (1) | 0.129 |
| Acute coronary syndrome | – | – | 81 | (29) | – | – | NA | 81 | (29) | – | – | NA |
| Days from cancer diagnosis to PCI/IHD admission, median (IQR) | – | – | 243 | (92–543) | – | – | NA | 242 | (90–547) | – | – | NA |
| Chemo/radiation/hormonal therapy | 10,220 | (37) | 97 | (34) | 10,123 | (37) | 0.079 | 97 | (35) | 94 | (34) | 0.023 |
| Surgery or endoscopic resection | 16,624 | (60) | 189 | (67) | 16,435 | (60) | 0.216 | 188 | (67) | 194 | (69) | 0.046 |
Data are presented as n (%) unless otherwise indicated
ACE angiotensin-converting enzyme, ARB angiotensin II receptor blocker, IHD ischaemic heart disease, IQR interquartile range, NA not available, PCI percutaneous coronary intervention, SD standardised difference, NA not available, PCI+ cancer patients undergoing PCI, PCI-/IHD cancer patients without IHD and not undergoing PCI